# Grifols, S.A. share price today (Grifols, S.A., GRFS)

> Grifols, S.A.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. GRFS · Healthcare · Drug Manufacturers - General · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/grfs

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: $8.56 (−8.6% in a year)
- P/E: 10.7×, against its own history
- Revenue (Jun 2026): $1.9 B (−0.9% on a year ago)
- Profit (Jun 2026): $154 M (+31.3% on a year ago)
- Operating margin: 15.9% (−1.6 points on a year ago)
- ROE: 5%, FY25
- ROIC: 6.5%, against a 9.1% cost of capital: −2.6 points

The main question: yearly earnings per share moved +156.5% while the share price moved −8.6%. ## What is the Grifols, S.A. share price today? Grifols, S.A.'s share price was $8.56 at the close on 3 November 2026. It has been stalling near its high for 2 weeks. That is 7.1% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. In the last 52 weeks it traded between $7 and $9, and at that close it sat 63% of the way up from that low. Over the last 10 years the share price moved −49% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Grifols, S.A. pay? Grifols, S.A. has 1 quarter of declared dividends on file, too few for a 12-month total. The most recent declaration was $0.15 for Jun 2025. Grifols, S.A. declared a dividend in 1 of the last 12 reported quarters, most recently $0.15 for Jun 2025. That is fewer than four quarters, so no 12-month total is shown. ## Which stock lists is Grifols, S.A. on? Grifols, S.A. is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Grifols, S.A. profitable? Grifols, S.A. earned $154 M of net profit in the Jun 2026 quarter, +31.3% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY25 profit was $402 M. Over 4 years profit has grown 20.8% a year on average. That is 8.2% of the quarter's revenue. The same quarter a year earlier earned $117 M. For the full year, FY25 profit was $402 M (+156.1% on the year before). Why profit moved: revenue changed −0.9% on a year earlier and the margin moved −1.6 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +60.3% and revenue −0.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Grifols, S.A. make, and is it growing? Grifols, S.A. reported $1.9 B of revenue in the Jun 2026 quarter, −0.9% on the same quarter a year earlier. Over 4 years it has grown 11.1% a year on average. The last full year, FY25, came in at $7.5 B. The last four reported quarters add to $7.4 B. FY25 revenue was $7.5 B, +4.3% on the year before. Recent pace: the last four quarters grew −0.3% on average, against 11.1% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −0.3%, against +4.4% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +51.9%, against +83.2% a year (rolling over). ## How much of every $100 of sales does Grifols, S.A. keep? Grifols, S.A.'s operating margin was 15.9% in the Jun 2026 quarter, 1.6 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 6 years it has been between 10.9% and 18.5%. The latest quarter is within that range. Across 6 years it has been between 10.9% and 18.5%, and FY25's 18.5% is the highest of them. Why the margin moved: operating margin changed −1.6 percentage points on the year while gross margin changed −2.2 points. So the drop came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Grifols, S.A.'s profit turning into cash? Over the last 3 years, 360% of Grifols, S.A.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $1.0 B of operating cash against $402 M of profit. After $265 M of spending on assets, $782 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Grifols, S.A.'s cash go? Grifols, S.A. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $722 M on assets over the last 3 years. Averaged over those years that is 3.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $722 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Grifols, S.A.'s P/E ratio, and how does it compare with its own history? Grifols, S.A.'s P/E is 10.7×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +156.5% while the price moved −8.6%. Earnings did better than the price, which pulled the multiple down within its own range. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Grifols, S.A. business getting better or worse? Grifols, S.A.'s business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 7.3%; each line tells part of the story. This is based on 12 quarters of 3 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Grifols, S.A. earn on its capital? Grifols, S.A. earned a ROE of 5% in FY25. That is up from a low of 1% in FY23. Its return on capital used (ROIC) is 2.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 5.3% net margin and 0.38× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 5.3% net margin × 0.38× asset turnover × 2.59× leverage (assets divided by equity) ≈ 5.2% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 6.5% − 9.1% = −2.6 percentage points. The 9.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Grifols, S.A. have too much debt? Grifols, S.A. has total debt of $9.4 B against shareholder equity of $8.0 B as of Jun 2026, so its debt is 1.17× its equity. Year by year, that ratio went from 1.39 in FY21 to 1.27 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Grifols, S.A. shareholding pattern? We have no ownership or short-position figures for Grifols, S.A., so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 11.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Grifols, S.A. from balance-sheet trouble? For Grifols, S.A., the Z-score is 1.12. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.12 is inside the danger zone, so the balance sheet is a real risk. ## How does Grifols, S.A. rank in its industry? 41.3 out of 100, rank 15 of 16 in Drug Manufacturers - General, with 71% of the evidence available. Grifols, S.A. scores 41.3 out of 100 against the 16 companies it is compared with in Drug Manufacturers - General, ranking 15. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 15 + 6.3 + 11.1 + 8.9 = 41.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Grifols, S.A. compared with? Grifols, S.A. ranks 15 of 16 Drug Manufacturers - General companies on the 4-Factor Sector Score, with 41.3 out of 100. 1. [Eli Lilly and Company](https://www.sectoralpha.in/us/stocks/lly) LLY · turning · Sector-leading setup · 85% evidence 83.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.0/35 · Revenue 45.5% · Profit 49.8% · Operating margin change 5.4 points · 95% evidence Capital efficiency 21.4/25 · ROCE 41.7% · Operating margin 53.7% · 76% evidence Valuation 11.9/20 · P/E 37.4× · PEG 0.74 · 65% evidence Relative strength 18.4/20 · Lead over its industry 15.6% · Lead over S&P 500 23.1% · 1 year 52.5% · 100% evidence · 3 of 12 weeks ahead Exact sum: 32 + 21.4 + 11.9 + 18.4 = 83.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [AbbVie Inc.](https://www.sectoralpha.in/us/stocks/abbv) ABBV · breaking out · Most evidence points up · 85% evidence 69.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.8/35 · Revenue 10.7% · Profit 100% · Operating margin change 1.8 points · 95% evidence Capital efficiency 19.4/25 · ROCE 24.5% · Operating margin 37.3% · 76% evidence Valuation 4.4/20 · P/E 44.8× · PEG 2.67 · 65% evidence Relative strength 16.4/20 · Lead over its industry 8.4% · Lead over S&P 500 15.4% · 1 year 30.5% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28.8 + 19.4 + 4.4 + 16.4 = 69 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Amgen Inc.](https://www.sectoralpha.in/us/stocks/amgn) AMGN · leader · Most evidence points up · 81% evidence 67.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 9.1% · Profit 32.1% · Operating margin change 2.9 points · 83% evidence Capital efficiency 15.2/25 · ROCE 18.2% · Operating margin 35.5% · 76% evidence Valuation 13.1/20 · P/E 22.4× · PEG 0.71 · 65% evidence Relative strength 15.4/20 · Lead over its industry 12.1% · Lead over S&P 500 19.3% · 1 year 44.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24.2 + 15.2 + 13.1 + 15.4 = 67.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Gilead Sciences, Inc.](https://www.sectoralpha.in/us/stocks/gild) GILD · leader · Evidence leans up · 75% evidence 63.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6.5% · Profit -147.6% · Operating margin change -1.8 points · 95% evidence Capital efficiency 19.4/25 · ROCE 30.3% · Operating margin 43.4% · 76% evidence Valuation 11.5/20 · P/E -47.8× · PEG n/a · 15% evidence Relative strength 17.6/20 · Lead over its industry 9.1% · Lead over S&P 500 16% · 1 year 40.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 14.6 + 19.4 + 11.5 + 17.6 = 63.1 · What this means: Relative strength against the index is 16%, and revenue and profit growth are weak. 5. [GSK plc](https://www.sectoralpha.in/us/stocks/gsk) GSK · basing · Evidence leans up · 81% evidence 60.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 5% · Profit 32.1% · Operating margin change 0.9 points · 83% evidence Capital efficiency 19.8/25 · ROCE 25.1% · Operating margin 30.9% · 76% evidence Valuation 14.5/20 · P/E 16.4× · PEG 0.39 · 65% evidence Relative strength 0.9/20 · Lead over its industry -15.7% · Lead over S&P 500 -10.3% · 1 year 4.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25 + 19.8 + 14.5 + 0.9 = 60.2 · What this means: Earnings are strong; relative strength in its sector is -15.7% and the one-year return is 4.4%. 6. [Bristol-Myers Squibb Company](https://www.sectoralpha.in/us/stocks/bmy) BMY · quiet · Evidence leans up · 81% evidence 59.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 3.1% · Profit 83.8% · Operating margin change 0.7 points · 83% evidence Capital efficiency 18.1/25 · ROCE 22.7% · Operating margin 34.4% · 76% evidence Valuation 14.3/20 · P/E 12.7× · PEG 0.5 · 65% evidence Relative strength 4.0/20 · Lead over its industry -5.7% · Lead over S&P 500 0.4% · 1 year 32.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 22.6 + 18.1 + 14.3 + 4 = 59 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [AstraZeneca PLC](https://www.sectoralpha.in/us/stocks/azn) AZN · turning · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.2/35 · Revenue 7.3% · Profit 17.4% · Operating margin change 3 points · 95% evidence Capital efficiency 14.2/25 · ROCE 17.6% · Operating margin 27.1% · 76% evidence Valuation 10.0/20 · P/E 22.9× · PEG 1.33 · 65% evidence Relative strength 7.3/20 · Lead over its industry -9.4% · Lead over S&P 500 -3.6% · 1 year 10.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 19.2 + 14.2 + 10 + 7.3 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Sanofi](https://www.sectoralpha.in/us/stocks/sny) SNY · turning · Evidence leans down · 66% evidence 49.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/35 · Revenue n/a · Profit n/a · Operating margin change 5.1 points · 39% evidence Capital efficiency 9.2/25 · ROCE 10.7% · Operating margin 21% · 76% evidence Valuation 14.5/20 · P/E 22.8× · PEG 0.33 · 65% evidence Relative strength 5.4/20 · Lead over its industry -10.8% · Lead over S&P 500 -5% · 1 year -8.7% · 100% evidence · 1 of 12 weeks ahead Exact sum: 20.6 + 9.2 + 14.5 + 5.4 = 49.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Organon & Co.](https://www.sectoralpha.in/us/stocks/ogn) OGN · turning · Evidence leans down · 81% evidence 49.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.3/35 · Revenue -2.5% · Profit -70.1% · Operating margin change -0.9 points · 83% evidence Capital efficiency 10.8/25 · ROCE 11.5% · Operating margin 20.7% · 76% evidence Valuation 15.5/20 · P/E 17× · PEG 0.17 · 65% evidence Relative strength 13.9/20 · Lead over its industry 15.2% · Lead over S&P 500 23% · 1 year 104.3% · 100% evidence · 0 of 12 weeks ahead Exact sum: 9.3 + 10.8 + 15.5 + 13.9 = 49.5 · What this means: Relative strength against the index is 23%, and revenue and profit growth are weak. 10. [Biogen Inc.](https://www.sectoralpha.in/us/stocks/biib) BIIB · breaking out · Evidence leans down · 81% evidence 46.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 7.9/35 · Revenue 0.3% · Profit -45.4% · Operating margin change -9.2 points · 83% evidence Capital efficiency 7.9/25 · ROCE 8.9% · Operating margin 25.1% · 76% evidence Valuation 13.3/20 · P/E 38.2× · PEG 0.38 · 65% evidence Relative strength 17.5/20 · Lead over its industry 12.8% · Lead over S&P 500 20.1% · 1 year 60.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 7.9 + 7.9 + 13.3 + 17.5 = 46.6 · What this means: Relative strength against the index is 20.1%, and revenue and profit growth are weak. 11. [Johnson & Johnson](https://www.sectoralpha.in/us/stocks/jnj) JNJ · turning · Evidence leans down · 75% evidence 46.3 out of 100 Growth Capital Valuation Relative
12. [Novartis AG](https://www.sectoralpha.in/us/stocks/nvs) NVS · turning · Evidence leans down · 85% evidence 46.0 out of 100 Growth Capital Valuation Relative
13. [Pfizer Inc.](https://www.sectoralpha.in/us/stocks/pfe) PFE · leader · Evidence leans down · 71% evidence 44.5 out of 100 Growth Capital Valuation Relative
14. [Merck & Co., Inc.](https://www.sectoralpha.in/us/stocks/mrk) MRK · leader · Evidence leans down · 85% evidence 41.9 out of 100 Growth Capital Valuation Relative
15. Grifols, S.A. this page GRFS · turning · Evidence leans down · 71% evidence 41.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.0/35 · Revenue -0.3% · Profit 51.7% · Operating margin change -1.6 points · 83% evidence Capital efficiency 6.3/25 · ROCE 7.3% · Operating margin 15.9% · 76% evidence Valuation 11.1/20 · P/E 12× · PEG n/a · 15% evidence Relative strength 8.9/20 · Lead over its industry -6.6% · Lead over S&P 500 -0.6% · 1 year 1.4% · 100% evidence · 1 of 12 weeks ahead Exact sum: 15 + 6.3 + 11.1 + 8.9 = 41.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 16. [Amarin Corporation plc](https://www.sectoralpha.in/us/stocks/amrn) AMRN · basing · Most evidence points down · 64% evidence 28.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - General](https://www.sectoralpha.in/us/sectors/drug-manufacturers-general), all 16 compared on one page. ## Which companies are close to Grifols, S.A. in size? Grifols, S.A. is the 15th largest of 17 Drug Manufacturers - General companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Bristol-Myers Squibb Company, Sanofi, GSK plc and Biogen Inc. Just below it: Organon & Co. and Amarin Corporation plc. ### Drug Manufacturers - General companies close in size

1. [Bristol-Myers Squibb Company](https://www.sectoralpha.in/us/stocks/bmy) $126.1 billion
2. [Sanofi](https://www.sectoralpha.in/us/stocks/sny) $108.1 billion
3. [GSK plc](https://www.sectoralpha.in/us/stocks/gsk) $97.4 billion
4. [Biogen Inc.](https://www.sectoralpha.in/us/stocks/biib) $36.8 billion
5. Grifols, S.A. $7.6 billion
6. [Organon & Co.](https://www.sectoralpha.in/us/stocks/ogn) $3.6 billion
7. [Amarin Corporation plc](https://www.sectoralpha.in/us/stocks/amrn) $254 million

[All 17 Drug Manufacturers - General companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-general#all-companies)

### Companies close in size in other industries

1. [VinFast Auto Ltd.](https://www.sectoralpha.in/us/stocks/vfs) $7.4 billion · Auto Manufacturers
2. [Clearwater Analytics Holdings, Inc.](https://www.sectoralpha.in/us/stocks/cwan) $7.4 billion · Software - Application
3. Grifols, S.A. $7.3 billion
4. [The Macerich Company](https://www.sectoralpha.in/us/stocks/mac) $7.3 billion · REIT - Retail
5. [South Bow Corporation](https://www.sectoralpha.in/us/stocks/sobo) $7.3 billion · Oil & Gas Midstream

## What else do people ask about Grifols, S.A.? ### What were Grifols, S.A.'s latest quarterly results? Grifols, S.A. reported revenue of $1.9 B and net profit of $154 M for the Jun 2026 quarter. Revenue fell 0.9% and profit rose 31.3% compared with a year earlier. Earnings per share were $0.23. The operating margin was 15.9%, 1.6 percentage points lower than a year earlier (as of 3 November 2026). ### What is Grifols, S.A.'s market cap? Grifols, S.A.'s market capitalisation is $7.6 B at a stock price of $8.56. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Grifols, S.A. performing? Grifols, S.A.'s share price has been stalling near its high for 2 weeks. In its latest quarter, revenue fell 0.9% and profit rose 31.3% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running (as of 3 November 2026). ### Will Grifols, S.A.'s stock price go up? This page does not forecast Grifols, S.A.'s stock price. What it shows instead: the stock price is $8.56, and it has been stalling near its high for 2 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Is Grifols, S.A.'s profit real cash? Yes, over the last 3 years, 360% of Grifols, S.A.'s reported profit came in as cash from operations. The latest year was lower at 260%, so the trend is worth watching. In FY25, operating cash was $1.0 B against reported profit of $402 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 3 November 2026). ### Where is Grifols, S.A. in its business cycle? Grifols, S.A.'s FY25 operating margin was 18.5%, against a 6-year range of 10.9% to 18.5%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 15.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Grifols, S.A. story? The main question: yearly earnings per share moved +156.5% while the share price moved −8.6%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Grifols, S.A. a stock worth studying right now? What the numbers show: Grifols, S.A.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.